Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia

Eşkazan, Ahmet Emre; Salihoğlu, Ayşe; Gültürk, Emine; Aydın, Şeniz Öngören; Tuzuner, Nukhet; Aydın, Yıldız

doi:10.1007/s12288-012-0173-8

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case of steroid-responsive AIHA has been reported in post-MDS acute myeloid leukemia (AML) [ 56 ]. Finally, AIN and steroid-refractory ITP has been documented in patients with acute promyelocytic leukemia [ 61 , 62 ].…”

Section: Autoimmune Complications In Myeloid Neoplasmsmentioning

confidence: 99%

Autoimmune Complications in Hematologic Neoplasms

Barcellini

Giannotta

Fattizzo

2021

Cancers

View full text Add to dashboard Cite

Autoimmune cytopenias (AICy) and autoimmune diseases (AID) can complicate both lymphoid and myeloid neoplasms, and often represent a diagnostic and therapeutic challenge. While autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are well known, other rarer AICy (autoimmune neutropenia, aplastic anemia, and pure red cell aplasia) and AID (systemic lupus erythematosus, rheumatoid arthritis, vasculitis, thyroiditis, and others) are poorly recognized. This review analyses the available literature of the last 30 years regarding the occurrence of AICy/AID in different onco-hematologic conditions. The latter include chronic lymphocytic leukemia (CLL), lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), myeloproliferative neoplasms, and acute leukemias. On the whole, AICy are observed in up to 10% of CLL and with higher frequencies in certain subtypes of non-Hodgkin lymphoma, whilst they occur in less than 1% of low-risk MDS and CMML. AID are described in up to 30% of myeloid and lymphoid patients, including immune-mediated hemostatic disorders (acquired hemophilia, thrombotic thrombocytopenic purpura, and anti-phospholipid syndrome) that may be severe and fatal. Additionally, AICy/AID are found in about 10% of patients receiving hematopoietic stem cell transplant or treatment with new checkpoint inhibitors. Besides the diagnostic difficulties, these AICy/AID may complicate the clinical management of already immunocompromised patients.

show abstract

Section: Autoimmune Complications In Myeloid Neoplasmsmentioning

confidence: 99%

Autoimmune Complications in Hematologic Neoplasms

Barcellini

Giannotta

Fattizzo

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Regarding MPN, including myelofibrosis (MF), various cases of RA, dermatomyositis, polyarteritis nodosa, multiple sclerosis, inflammatory bowel disease, and primary biliary cirrhosis have been reported ( 11 , 12 ). AML is also occasionally associated with AID as well as with AIC ( 13 , 14 ). Finally, case-reports/small series of immune-mediated hemostatic disorders have been described in MDS, CMML, MPN, and AML.…”

Section: Epidemiological Association Of Autoimmune Diseases and Myeloid Neoplasmsmentioning

confidence: 99%

Immune Phenomena in Myeloid Neoplasms: An “Egg or Chicken” Question

Barcellini

Fattizzo

2021

Front. Immunol.

View full text Add to dashboard Cite

Immune phenomena are increasingly reported in myeloid neoplasms, and include autoimmune cytopenias/diseases and immunodeficiency, either preceding or complicating acute myeloid leukemia, myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, and bone marrow failure (BMF) syndromes. Autoimmunity and immunodeficiency are the two faces of a dysregulated immune tolerance and surveillance and may result, along with contributing environmental and genetic factors, in an increased incidence of both tumors and infections. The latter may fuel both autoimmunity and immune activation, triggering a vicious circle among infections, tumors and autoimmune phenomena. Additionally, alterations of the microbiota and of mesenchymal stem cells (MSCs) pinpoint to the importance of a permissive or hostile microenvironment for tumor growth. Finally, several therapies of myeloid neoplasms are aimed at increasing host immunity against the tumor, but at the price of increased autoimmune phenomena. In this review we will examine the epidemiological association of myeloid neoplasms with autoimmune diseases and immunodeficiencies, and the pivotal role of autoimmunity in the pathogenesis of MDS and BMF syndromes, including the paroxysmal nocturnal hemoglobinuria conundrum. Furthermore, we will briefly examine autoimmune complications following therapy of myeloid neoplasms, as well as the role of MSCs and microbiota in these settings.

show abstract

Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia

Cited by 2 publications

References 13 publications

Autoimmune Complications in Hematologic Neoplasms

Autoimmune Complications in Hematologic Neoplasms

Immune Phenomena in Myeloid Neoplasms: An “Egg or Chicken” Question

Contact Info

Product

Resources

About